Surgeon General nominee Nicole Saphier will divest tobacco stocks PM, MO, and BTI following her September 16 confirmation hearing to avoid conflicts of interest amid a shifting industry landscape.
FDA authorization for Zyn nicotine pouches and strong smoke-free product growth underpin a positive outlook for Philip Morris.
Resilient pricing and smokeless product expansion, along with a new agreement with Philip Morris, support Altria's outlook despite declining cigarette volumes.
Restructuring, job cuts, and litigation risks are balanced by cheap valuation and analyst expectations for EPS growth.
President Trump's Surgeon General nominee, Nicole Saphier, has pledged to divest her holdings in Philip Morris International, Altria Group, and British American Tobacco within 90 days of confirmation. The move aims to eliminate potential conflicts of interest as the tobacco industry pivots toward smoke-free alternatives to combat declining cigarette volumes.
To avoid potential conflicts of interest with the public health mandate of the Surgeon General role, the nominee is required to divest these holdings within 90 days of confirmation.